In our cohort study, data including PD-L1 TPS and tumor mutation burden were not collected; considering the high cost of testing and the fact that the testing items are not included in medical insurance, most patients are unwilling to do the testing, which makes it impossible for us to know the correlation between the level of PD-L1 stratification and the efficacy of combined immune therapy. The gene discussed is CD274; the disease is neoplasm.